Recombinant ADAMTS1 promotes muscle cell differentiation and alleviates muscle atrophy by repressing NOTCH1 Authors: Sang Hyup Lee, Sang Yoon Kim, Yun Gu Gwon, Chanwoo Lee, Changhwan Kim, Ick Hyun Cho, Tae-Won Kim, & Bong-Keun Choi Published: 2024 ABSTRACT AbstractA disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) plays crucial roles in various biological processes, including myogenesis, by modulating the neurogenic locus notch homolog protein 1 (NOTCH1) signaling pathway. However, the mechanisms through which ADAMTS1 regulates myogenesis remain unclear. In this study, we generated recombinant ADAMTS1 mutants and determined their effects on muscle cell differentiation, focusing on the regulation of NOTCH1 signaling. Treatment of C2C12 cells with recombinant ADAMTS1 protein enhanced muscle cell differentiation. Meanwhile, ADAM10 treatment inhibited muscle differentiation through the activation of NOTCH1 cleavage. Recombinant ADAMTS1 reversed ADAM10-induced muscle cell atrophy by suppressing NOTCH1 activation and downregulating its target gene. Recombinant ADAMTS1 also alleviated dexamethasone-induced muscle atrophy in a mouse model. In summary, our findings suggest that recombinant ADAMTS1 promotes muscle regeneration by suppressing NOTCH1 and highlight the potential of recombinant ADAMTS1 proteins in the treatment of muscle wasting disease.Keywords: Muscle atrophy, Muscle cell differentiation, Myogenesis, NOTCH1, Recombinant ADAMTS1 INTRODUCTION The ADAMTS protease superfamily exhibits zinc metalloproteinase activity. In mammals, 19 ADAMTS proteases and seven ADAMTS-like proteins contain highly conserved domains. The superfamily consists of a pro-domain, a metalloproteinase, and a disintegrin domain, followed by an ancillary domain composed of thrombospondin 1, a Cys-rich module, and a spacer (1, 2). ADAMTS1, a member of the ADAMTS superfamily, regulates various biological processes, such as fertility and angiogenesis (3). Recent findings indicate that ADAMTS1 suppresses NOTCH1 signaling via its metalloproteinase activity, leading to enhanced muscle satellite cell activation (4). NOTCH1 is a transmembrane protein that mediates cell-to-cell communication and plays critical roles in diverse developmental and physiological processes (5). NOTCH1 cleavage is a critical step in the NOTCH1 signaling pathway. The S2 cleavage is mediated by the ADAM10 or ADAM17 metalloproteinase, which are expressed on the cell surface, followed by S3 cleavage mediated by γ-secretase to release the notch intracellular domain (NICD). The NICD then translocates into the nucleus to regulate its target genes (6-8). In this manner, it promotes the self-renewal of muscle satellite cells located between the basal lamina and plasmalemma of myofibers (9, 10). This self-renewal process is tightly controlled as the number of satellite cells within skeletal muscle is kept constant (11). The mechanisms through which NOTCH1 signaling regulates satellite cells remain unclear. However, several lines of evidence have suggested that macrophage-secreted ADAMTS1 targets NOTCH1 and stimulates muscle satellite cells to promote muscle regeneration (4, 9). The pro-domain and a metalloproteinase domain of ADAMTS1 are sufficient for NOTCH1 binding (4). However, it is unclear whether these domains are required to promote muscle differentiation and stimulate myogenesis by targeting NOTCH1. Herein, we investigated the effect and potential mechanisms of recombinant ADAMTS1 in muscle cell differentiation and muscle atrophy through its interaction with NOTCH1. RESULTS Generation of a highly expressed recombinant ADAMTS1 mutant To generate mutant ADAMTS1, we first constructed an ADAMTS1 PM-truncated mutant, which is essential for myogenesis and consists of the pro-domain and metalloproteinase domain (4). Random deletion mutants were then generated, among which recombinant ADAMTS1 NM3 was highly expressed (Fig. 1A). To analyze the properties of NM3 and improve its purity, proteins were concentrated or treated with 1M ammonium sulfate. Additional protein expression was detected only under non-reducing conditions, at double the size of NM3. Considering that protein expression was not upregulated under reducing condition, the increase under non-reducing condition could be attributed to disulfide bond formation (Fig. 1B). As greater protein expression due to disulfide bond formation was detected even after purification via affinity chromatography, we considered that the disulfide bond was formed by recombinant NM3. Size-exclusion high-performance liquid chromatography (SE-HPLC) analysis showed the coexistence of monomeric and dimeric NM3 recombinant proteins. Additionally, the expression of dimeric NM3 protein increased under various conditions (Fig. 1C). Recombinant ADAMTS1 generation and characterization. (A) Schematic representation of recombinant ADAMTS1 mutant. (B, C) Characterization of recombinant ADAMTS1 NM3. Proteins were analyzed under non-reducing and reducing conditions using SDS-PAGE (B) and SE-HPLC (C): (1) purified protein supernatant, (2) purified protein incubated at room temperature for 2 d, (3) concentrated protein, (4) 1M ammonium sulfate added to the cell culture media, and (5) 1M ammonium sulfate added to the solution. (D, E) Characterization of the recombinant ADAMTS1 C198S. Proteins were analyzed under non-reducing and reducing conditions using SDS-PAGE (D) and SE-HPLC (E) of (1) purified protein supernatant and (2) concentrated protein. Pro, pro-domain; MP, metalloproteinase. We performed peptide mapping and protein sequence analysis to identify 11 cysteine residues in the NM3 protein. Cys-198, a cysteine-switch motif, was thought to randomly form disulfide bonds with the cysteines of other NM3 proteins. To generate a dimerization-inhibited recombinant ADAMTS1 protein, a point mutation was introduced to change the 198th amino acid from cysteine to serine (Fig. 1A). The C198S mutant was expressed in monomeric form even under non-reducing conditions (Fig. 1D). Moreover, it formed monomeric protein even after concentration, as validated using SE-HPLC analysis (Fig. 1E). Recombinant ADAMTS1 promotes muscle cell differentiation via NOTCH1 binding C2C12 cells were treated with ADAMTS1 PM, NM3, or C198S recombinant proteins to determine whether recombinant ADAMTS1 proteins can promote muscle cell differentiation. Treatment with NM3 and C198S recombinant proteins significantly enhanced C2C12 cell differentiation, with the C198S protein exerting the greatest differentiation-promoting effect (Fig. 2A). C198S protein-treated C2C12 cells formed the thickest myotubes (Fig. 2B), with the highest fusion index (Fig. 2C). ADAMTS1 has been suggested to bind NOTCH1 and regulate myogenesis via inhibition of NOTCH1 signaling (4). Therefore, we investigated whether recombinant ADAMTS1 can bind NOTCH1. Lysates from NOTCH1-overexpressing C2C12 cells were treated with purified His-tagged NM3 and C198S recombinant proteins. Immunoprecipitation (IP) assays showed that recombinant ADAMTS1 bound to NOTCH1 (Fig. 2D). Overall, these data suggest that recombinant ADAMTS1 proteins, most notably C198S, promote muscle cell differentiation via NOTCH1 binding. Effect of recombinant ADAMTS1 on muscle cell differentiation. (A) Immunofluorescent staining of C2C12 cells. Cells were treated with each recombinant ADAMTS1 protein at concentrations of 10 and 100 ng/ml. Scale bar: 100 μm. (B, C) Quantification of differentiated myotube diameter (B) and fusion index (C). Labels are named as “mutant name-concentration (L/H).” (D) Analysis of the binding between recombinant ADAMTS1 and NOTCH1 using immunoprecipitation assay. Data are presented as the mean ± standard δeviation. Statistical significance was tested using one-way ANOVA with Tukey’s post hoc test, *P < 0.05. Con, control; L, low (10 ng/ml); H, high (100 ng/ml). Recombinant ADAMTS1 inhibits ADAM10-mediated NOTCH1 activation C2C12 cells were transfected with ADAMTS1-targeting siRNA to confirm the muscle cell differentiation-promoting effects of recombinant ADAMTS1 (Supplementary Fig. 1A). ADAMTS1 knockdown significantly suppressed muscle cell differentiation. However, treatment with recombinant ADAMTS1 reversed this effect (Fig. 3A, B). Inhibitory effect of recombinant ADAMTS1 on ADAM10-mediated NOTCH1 activation. (A, B) ADAMTS1 knockdown C2C12 cells were treated with recombinant ADAMTS1 protein at a concentration of 100 ng/ml. Differentiated myotubes were visualized using Jenner’s staining (A), and the myotube length was measured (B). Scale bar: 500 μm. *P < 0.05, **P < 0.01, ***P < 0.001. (C) Effect of ADAM10 on muscle cell differentiation. Recombinant ADAM10 protein was added at concentrations of 0.1, 1, 10, and 100 ng/ml. Differentiated myotube length was measured. ***P < 0.001. (D) Western blotting analysis of ADAM10-treated C2C12 cells. Quantification of protein expression using ImageJ software. ***P < 0.001. (E) Immunofluorescence staining of C2C12 cells. Cells were treated with recombinant ADAM10 at 10 ng/ml and recombinant ADAMTS1 at 0 (untreated), 1, 10, 100, and 1000 ng/ml. Scale bar: 100 μm. (F) Western blotting analysis of C2C12 cells treated with recombinant ADAM10 at 10 ng/ml and recombinant ADAMTS1 at 0 (untreated), 1, 10, 100, and 1000 ng/ml. Protein expression was quantified using ImageJ software. †P < 0.05, ††P < 0.01, †††P < 0.001 compared to control group, *P < 0.05, **P < 0.01, ***P < 0.001 compared to recombinant ADAMTS1 untreated group. (G) Quantification of Hes1 mRNA expression. †P < 0.05 compared to control group, **P < 0.01 compared to the untreated group. Data are presented as the mean ± standard deviation. Statistical significance was tested using one-way ANOVA with Tukey’s post hoc test. Con, control; si-ctrl, control siRNA; si-ATS #1, ADAMTS1 siRNA #1; si-ATS #2, ADAMTS1 siRNA #2; rA, recombinant ADAMTS1. NOTCH1 activation requires serial proteolytic cleavage mediated by ADAM10 and γ-secretase at the S2 and S3 cleavage sites, respectively (6-8). Therefore, we investigated whether ADAM10 suppresses muscle cell differentiation via NOTCH1 activation. As expected, ADAM10 treatment suppressed muscle cell differentiation (Fig. 3C and Supplementary Fig. 1B). To confirm the suppressive effect of ADAM10 on muscle differentiation at the molecular level, we detected muscle differentiation-related biomarkers, including myogenic differentiation 1 (MyoD), myogenin, and myosin heavy chain (MyHC). ADAM10 treatment downregulated all three, while upregulating NICD expression via NOTCH1 activation (Fig. 3D and Supplementary Fig. 1C). Next, we investigated whether recombinant ADAMTS1 can inhibit the ADAM10-mediated suppression of muscle cell differentiation. Although ADAM10 decreased myotube diameter and fusion index, treatment with recombinant ADAMTS1 promoted muscle cell differentiation in a dose-dependent manner (Fig. 3E and Supplementary Fig. 1D and E). In addition, recombinant ADAMTS1 significantly reversed the ADAM10-mediated suppression of biomarkers related to muscle cell differentiation and downregulated NICD levels (Fig. 3F and Supplementary Fig. 1F). Moreover, hairy and enhancer of split 1 (Hes1), a downstream target gene of NOTCH1, was downregulated by recombinant ADAMTS1 (Fig. 3G). Overall, these findings suggest that recombinant ADAMTS1 reverses the ADAM10-inducing suppression of muscle cell differentiation, restoring myogenesis via NOTCH1 repression. Recombinant ADAMTS1 alleviates muscle atrophy To confirm the effects of recombinant ADAMTS1 in vivo, we induced muscle atrophy in mice using dexamethasone. Although there was a decrease in muscle weight after 12 d of dexamethasone injection, treatment with recombinant ADAMTS1 significantly increased the weights of the tibialis anterior (TA) and gastrocnemius (GA) muscles (Fig. 4A, B). Histological analysis confirmed that recombinant ADAMTS1 treatment reversed dexamethasone-induced TA atrophy (Fig. 4C). The ameliorative effect of recombinant ADAMTS1 on muscle atrophy was also confirmed based on an increase in the cross-sectional area (CSA) of TA muscle fibers (Fig. 4D). In addition, recombinant ADAMTS1 restored myosin heavy chain levels, while suppressing NICD levels (Fig. 4E). The mRNA expression of Atrogin1 and Muscle ring finger 1 (Murf1), well-known muscle atrophy-related factors, was downregulated by recombinant ADAMTS1 in our mouse model (Fig. 4F). Collectively, these results indicate that recombinant ADAMTS1 alleviates muscle atrophy. Recombinant ADAMTS1 alleviates muscle atrophy. (A, B) Weights of TA (A) and GA (B) muscles in mice with dexamethasone-induced atrophy. Recombinant ADAMTS1 was injected at a concentration of 1 mg/kg (Low) or 10 mg/kg (High). *P < 0.05, **P < 0.01, ***P < 0.001. (C, D) Histological analysis of the TA muscle. H&E-stained sections (C) and CSA of TA muscle (D). Scale bar: 100 μm. (E) Western blotting analysis of tibialis anterior muscle. (F) Quantification of the mRNA expression of muscle atrophy-related factors Atrogin1 and Murf1. †P < 0.05, ††P < 0.01 compared to the control group, *P < 0.05 compared to the dexamethasone group. Data are presented as the mean ± standard deviation. Statistical significance was tested using one-way ANOVA with Tukey’s post hoc test. Dexa, dexamethasone; rAL, recombinant ADAMTS1 Low (1 mg/kg); rAH, recombinant ADAMTS1 High (10 mg/kg). DISCUSSION In the present study, we investigated the effects of recombinant ADAMTS1, focusing on its pro-domain and metalloproteinase domain, on muscle cell differentiation and muscle atrophy through interaction with NOTCH1. Our findings provide novel insights into the molecular mechanisms regulating muscle regeneration and highlight the therapeutic potential of recombinant ADAMTS1 in muscle-wasting diseases. The NOTCH1 downstream gene Hes1 regulates myogenic factor MyoD and NOTCH1 ligand Dll1 to maintain the muscle satellite cell pool (12). ADAMTS1 Tg mice show reduced expression of Hes1 and Hey1, and the phenotype of their satellite cells resembles that of the NOTCH signaling-suppressed satellite cell population (4, 13, 14). Although several findings suggest that ADAMTS1 inhibits NOTCH1 signaling and that ADAMTS1 has a potential application for the treatment of muscle atrophy (4, 15-17), the effect of purified recombinant ADAMTS1 on muscle cell differentiation remains unknown. In this study, to identify crucial domains for NOTCH1 interaction, mutant ADAMTS1 recombinant proteins were generated with random deletions in specific genes, and irregular dimeric proteins were found at the 198th cysteine, which is known as a cysteine switch motif that is highly conserved in the ADAMTS family (18, 19). Based on these findings, a C198S mutant was generated with a point mutation in the cysteine switch motif of NM3. Notably, the resulting C198S mutant showed enhanced differentiation of C2C12 cells through interaction with NOTCH1. A previous report suggested that the pro-domain and metalloproteinase domain of ADAMTS1 are essential for NOTCH1 binding (4). We confirmed NOTCH1 binding and muscle differentiation in proteins with mutations where the region near the active site of the metalloproteinase domain is preserved, and observed reduced activity in cases where it is not. Therefore, the essential site for NOTCH1 binding is expected to be near the active site, however, it remains to be identified. A previous study showed that ADAM10 suppression enhances muscle regeneration after injury (20). Therefore, we induced a C2C12 cellular model of muscle atrophy through ADAM10 treatment. Indeed, ADAM10 suppressed muscle cell differentiation, downregulated muscle differentiation-associated proteins, such as MyoD, myogenin, and MyHC, in a dose-dependent manner, and upregulated NICD expression. However, recombinant ADAMTS1 reversed the ADAM10-mediated suppression of muscle cell differentiation, as evidenced by an increased myotube diameter and fusion index. Moreover, recombinant ADAMTS1 treatment enhanced the protein expression of MyoD, myogenin, and MyHC, while downregulating NICD protein levels and Hes1 mRNA expression. To confirm the effects of recombinant ADAMTS1 in vivo, we generated a mouse model of dexamethasone-induced muscle atrophy (21). Treatment with recombinant ADAMTS1 significantly increased the weights of TA and GA muscles in mice with dexamethasone-induced muscle atrophy, which was confirmed by measuring the myofiber CSA. Recombinant ADAMTS1 also suppressed NICD and upregulated MyHC in mice. The muscle-specific E3 ligases Atrogin1 and Murf1 are well-known muscle atrophy markers (22, 23). In this study, recombinant ADAMTS1 suppressed the upregulation of mRNA Atrogin1 and Murf1 under induced atrophy conditions. Collectively, these findings suggest that recombinant ADAMTS1 promotes muscle cell differentiation and alleviates muscle atrophy via suppression of ADAM10-mediated NOTCH1 activation. At present, the molecular mechanisms underlying muscle atrophy remain incompletely understood. Most previous studies have focused on the inhibition of muscle protein degradation and inflammatory responses. Various active substances and small-molecule compounds have been explored for targeting the PI3K/AKT/FoxO or myostatin pathway (24, 25). Conversely, a novel recombinant protein derived from ADAMTS1 enhanced the differentiation of muscle cells via inhibition of Hes1 which is known to regulate muscle satellite cell activation (26). Therefore, the current study elucidated not only the mechanism in terms of the inhibition of muscle degradation, but also with respect to promoting muscle differentiation. Conclusively, our findings indicate that ADAMTS1 plays a crucial role in muscle regeneration, and recombinant ADAMTS1 holds promise as a therapeutic agent for muscle-wasting diseases by inhibiting muscle degradation and promoting regeneration. The recombinant protein derived from ADAMTS1 has potential therapeutic applications for conditions such as sarcopenia, muscular dystrophies, cachexia, and disuse atrophy, offering a novel approach that extends beyond traditional therapies aimed solely at preventing muscle loss. However, given the diverse roles that NOTCH1 plays in body tissues, especially its involvement in various differentiation and cellular processes, further research is needed to evaluate whether recombinant ADAMTS1 specifically affects muscle differentiation and NOTCH1 regulation, as well as to minimize the risk of potential side effects. MATERIALS AND METHODS Cloning The full-length ADAMTS1 cDNA (OHu62902, GenScript) was subcloned into the mammalian expression vector pEF6/v5-His (V96120, Invitrogen). Various deletions and point mutants of ADAMTS1 were generated using the In-fusion HD cloning kit (639650, Clontech) and specific primer sets, according to the manufacturer’s protocol. All generated plasmids were verified through sequencing. Cell culture and differentiation C2C12 cells (CRL-1772, ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) and incubated in a humidified incubator at 37°C and 5% CO2. For muscle cell differentiation, C2C12 cells were cultured in DMEM supplemented with 2% horse serum for 7 d, and the culture medium was changed every 3 d. To generate a NOTCH1-overexpressing C2C12 cell line, C2C12 cells were transfected with 1 μg of pcDNA3.1(+) C-Myc-NOTCH1 vector using Lipofectamine 2000 reagent (11668019, Invitrogen). After 48 h, the cells were incubated with 800 μg/ml G418 for clonal selection. Colonies were selected for 2 weeks, and expression was confirmed via western blotting using anti-Myc antibodies (05-724, Sigma Aldrich). CHO-K1 cells (CCL-61, ATCC) were cultured in RPMI1640 medium supplemented with 10% FBS and 1% P/S and transfected with plasmids using the Lipofectamine 2000 reagent, according to the manufacturer’s protocol. Transfected CHO-K1 cells were incubated with 5 μg/ml of blasticidin to establish a mutant ADAMTS1-overexpressing cell line. Recombinant protein production and purification CHO-K1 overexpression cell lines were cultured in BASAL3 chemically defined medium (Ajinomoto, Tokyo, Japan). For recombinant protein production, the cells were cultured in BASAL3 medium for 7 d, followed by the addition of 5% (v/v) FEED2 (Ajinomoto) to the medium every 3 d for an additional 7 d. Recombinant mutant ADAMTS1 protein was purified from the culture supernatant using Ni-NTA agarose affinity chromatography (30210, Qiagen). Recombinant ADAM10 was purchased from R&D systems (936-AD). Western blotting and IP assay For western blot analysis, cells were lysed using CelLytic M buffer (C2978, Sigma Aldrich). For IP assays, purified ADAMTS1 proteins were treated with lysates of Myc-tagged NOTCH1-overexpressing cells in vitro. Thereafter, the cell lysate and purified protein mixture were immunoprecipitated using an anti-Myc antibody and protein A/G magnetic beads (88803, Thermo Fisher Scientific). The antibodies used in this study were anti-Myc (05-724, Sigma Aldrich), anti-6x-His (MA5-33032, Invitrogen), anti-ADAMTS1 (12897S, Cell signaling), anti-MyoD (ab203383, Abcam), anti-Myogenin (sc-12732, Santa Cruz), anti-MyHC (05-716, Millipore), anti-NICD (3608S, Cell signaling), and anti-β-actin (sc-47778, Santa Cruz Biotechnology). Immunofluorescence (IF) staining C2C12 cells were seeded in a 24-well plate (1 × 105 cells/well) and incubated at 37°C with 5% CO2 until cell confluence reached over 90%. Thereafter, the cells were cultured in DMEM containing 2% horse serum. Cells were fixed with 4% formaldehyde, permeabilized with 0.25% Triton X-100 in PBS, blocked with 2% BSA, and incubated with an anti-MyHC antibody (05-716, Millipore). Cells were incubated with Alexa Fluor 488 (A-11001, Invitrogen) or 555 secondary antibodies (A-21422, Invitrogen). Finally, the cell nuclei were stained with DAPI (D9542, Sigma-Aldrich) and visualized using a Nikon Eclipse Ts2-FL microscope (Nikon, Japan). Fusion index was defined as the percentage of nuclei located in myosin heavy chain-positive cells. Fusion index and myotube diameter were measured at least 10 fields of view and quantified with biological triplicates using NIS-Element imaging software. siRNA siRNAs targeting ADAMTS1 were purchased from Bioneer (11504, Republic of Korea). C2C12 cells were transfected with siRNAs using Lipofectamine 2000. Jenner’s staining C2C12 cells were seeded in a 24-well plate (1 × 105 cells/well) and incubated at 37°C under a 5% CO2 condition until cell confluence reached over 90%. Thereafter, the cells were cultured in DMEM containing 2% horse serum. Differentiated cells were fixed with 100% methanol after 7 d of muscle cell differentiation and stained with Jenner’s staining solution (J1625, Sigma Aldrich). Finally, differentiated muscle cells were observed using a Nikon Eclipse Ts2-FL microscope and quantified using NIS-Element imaging software. SE-HPLC SE-HPLC was performed on a Waters e2695 separation module (Waters, USA) equipped with a TSKGEL G3000SWXL column. Sodium phosphate buffer (pH 6.8) was used as the mobile phase, with a flow rate of 1 ml/min. Recombinant protein samples (50 μg) were injected at a concentration of 1 mg/ml. The SE-HPLC peaks were detected at 280 nm. Animals Male C57BL/6 mice (12-week-old) were obtained from Orient Bio (Seongnam, Republic of Korea), housed under standard laboratory conditions (temperature, 22 ± 2°C; humidity, 50 ± 10%; and 12-h light/dark cycle), and fed regular chow (SAMTAKO, Republic of Korea). After a 1-week acclimation period, mice were intraperitoneally (IP) injected with dexamethasone (50 mg/kg) for 12 d to induce atrophy. Recombinant ADAMTS1 was IP injected at a 3-d interval at concentrations of 1 mg/kg (Low) and 10 mg/kg (High). All experimental procedures were approved by the Animal Care and Use Committee of INVIVO Co., Ltd. (IV-RA-22-2002-07). Histological analysis TA muscles were fixed in 4% paraformaldehyde, paraffin-embedded, cut into sections using a microtome, and stained with hematoxylin and eosin (H&E). The cross-sectional area of myofibers was measured using ImageJ software. Quantitative RT-PCR Total RNA was isolated using the RNeasy mini kit (74104, Qiagen) and reverse-transcribed into cDNA using GoScript reverse transcriptase (A2790, Promega). Quantitative RT-PCR was performed using QuantStudio3 (Applied Biosystems, USA). The following primers were used for Hes1 (Forward, 5’-ACCTTCCAGTGGCTCCTC-3’; Reverse, 5’- TTTAGTGTCCGTCAGAAGAGAG-3’), Gapdh (Forward, 5’-TCACCACCATGGAGAAGGC-3’; Reverse, 5’-GCTAAGCAGTTGGTGGTGCA-3’), Atrogin1 (Forward, 5’-AGAAAAGCGGCAGCTTCGT-3’; Reverse, 5’-GCTGCGACGTCGTAGTTCAG-3’), and Murf1 (Forward, 5’-ACACAACCTCTGCCGGAAGT-3’; Reverse, 5’-ACGGAAACGACCTCCAGACA-3’). Statistical analysis Data are presented as the mean ± standard deviation. All statistical analyses were performed using GraphPad Prism (CA, USA), and significant differences were determined using one-way ANOVA and Tukey’s post hoc test. Supplementary Material ACKNOWLEDGEMENTS This research was supported by the Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (RS-2022-00165803, Republic of Korea). Footnotes CONFLICTS OF INTEREST The authors have no conflicting interests. REFERENCES Associated Data Supplementary Materials